CELCUITY LLC reports a Return on Equity (ROE) of -360.37%.

What is CELC's dividend yield?

CELCUITY LLC offers a dividend yield of 0.00%.

What is CELC's Quality Score?

Our AI rates CELC's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.

Is now a good time to buy CELC?

Our AI Timing Score for CELC is 27 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.

Which sector does CELC belong to?

CELCUITY LLC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange

CELC (NASDAQ) Stock Analysis | CELCUITY LLC

Stock Check Daily update data at 8:30 AM
(Price: 2026-07-31 | FS: 2026-03-31)

CELC AI Analysis Summary

Our AI summary for CELC: CELCUITY LLC (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 0.00, ROE of -360.37%, a dividend yield of 0.00%. Its financial Quality Score stands at 31/100 — fundamentals below the market average. The AI Timing Score is 27/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.

CELC

CELCUITY LLC

US:NASDAQ STOCK Healthcare >> Biotechnology

USD 86.38

-1.26 (-1.44%) Day Change

Watchlist Portfolio Compare Chart

6.04

D/E

-360.4%

ROE

-47.0%

ROA

0.00%

Div Yield

CELCUITY LLC
TYPE: STOCK
MARKET: NASDAQ

Compare Watchlist Myport

USD 86.38 Price -1.26 (-1.44%) Day Change	NEWS SCORE: N/A

CELC, the overall quality is not good ( Quality = 31) and the timing to buy is ...(Sign In to See)...

Loading chart...

31 QUALITY

Signal: UNDERPERFORM

Signal Description: Company financial health is Not Good

Reason: ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.

88 Sign in

TIMING

Signal: OUTPERFORM

Signal Descri...: Good

Reason: Momentum indicators aligned on the daily timeframe

Unlock timing signals and detailed reasons

In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...

Quality Factors

45%

In Recommendations?	Not in any sections
Select Rate	0.00 From 30 days period
Watch Rate	0.00 From 30 days period
News Score	N/A
Magic Formula Rank by ROA	N/A
Magic Formula Rank by ROE	N/A
Magic Formula Rank by ROIC	N/A
Price	86.38
PBV / Sector	79.85 / 5.20
Earning Per Share	-3.90

PE / Sector	N/A / 19.97
PEG or PE/Growth / Sector	N/A / 1.22
Average 1M Daily Value	161.82 M GREAT
Average 1W Daily Value	107.41 M GREAT

Timing Factors

42%

MACD	SIGN IN
MACD Signal	SIGN IN
MACD Divergence	SIGN IN
RSI	SIGN IN
Stochastic Oscillator K	SIGN IN
Stochastic Oscillator D	SIGN IN
ADX	SIGN IN
Avg 5 day Timing Score	SIGN IN

Financial Health

41%

DE / Sector	SIGN IN
DE Average / Sector	SIGN IN
DE Change Average (%) / Sector	SIGN IN
Current Ratio / Sector	SIGN IN
Current Ratio Average / Sector	SIGN IN
Current Ratio Change Average (%) / Sector	SIGN IN
Quick Ratio / Sector	SIGN IN
Quick Ratio Average / Sector	SIGN IN
Quick Ratio Change Average (%) / Sector	SIGN IN
FCF/Share / Sector	SIGN IN
FCF/Share Average / Sector	SIGN IN
FCF/Share Change Average (%) / Sector	SIGN IN

Ability to Make Profit

43%

GPM (%) / Sector	SIGN IN
GPM Average (%) / Sector	SIGN IN
GPM Change Average (%) / Sector	SIGN IN
OPM (%) / Sector	SIGN IN
OPM Average (%) / Sector	SIGN IN
OPM Change Average (%) / Sector	SIGN IN
NPM (%) / Sector	-125,250.65 / 98.71
NPM Average (%) / Sector	-120,106.49 / -1,721.76
NPM Change Average (%) / Sector	N/A / 5,211.62
Asset Turnover / Sector	SIGN IN
Asset Turnover Average / Sector	SIGN IN
Asset Turnover Change Average (%) / Sector	SIGN IN
ROA (%) / Sector	-47.03 / 27.02
ROA Average (%) / Sector	-37.38 / -368.17
ROA Change Average (%) / Sector	22.26 / 5,404.12 GREAT
ROE (%) / Sector	-360.37 / 3.47
ROE Average (%) / Sector	-141.78 / 6.51
ROE Change Average (%) / Sector	87.47 / 2,128.13 GREAT
ROIC (%) / Sector	SIGN IN
ROIC Average (%) / Sector	SIGN IN
ROIC Change Average (%) / Sector	SIGN IN

Return to Investors

Dividend (%) / Sector	N/A / 0.04
Dividend Average (%) / Sector	N/A / 17.04
Dividend Change Average (%) / Sector	N/A / -1.75

Registration Details

Analyze Date	2026-08-01 07:59:37
Symbol	CELC
Name	CELCUITY LLC
Sector	Healthcare >> Biotechnology
Market	NASDAQ
Listed Shares	48.77 M
Par Value	N/A
Calculated From	Quarter
Sign	N/A
Market Cap (M.USD) / Sector Average	4,273.88 / 9,903.94

News, Concensus, ...

Estimation Consensus	See at WSJ.com
Full details	See at WSJ.com
Chart	See in Chart feature
News	See at Yahoo Finance

Address: 2800 Campus Drive, Minneapolis, MN, United States, 55441

Phone: (763) 392-0123

Website: https://www.celcuity.com

Employees: 155

Sector: Healthcare >> Biotechnology

Description: Celcuity Inc., a clinical-stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's lead drug candidate includes Gedatolisib, which selectively targets various Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic targets of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2 to treat patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-) or HR+/HER2-, advanced or metastatic breast cancer (ABC), and patients with metastatic castration resistant prostate cancer (mCRPC). The company had a license agreement with Pfizer Inc. for the development and commercialization rights to Gedatolisib. Celcuity Inc. was incorporated in 2011 and is based in Minneapolis, Minnesota.